Persistent Methicillan Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Multiple systemic antibiotics
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
The study will look at the safety and effectiveness of a 28 day-course of vancomycin for inhalation in getting rid of the bacteria, Methicillan Resistant Staphylococcus Aureus (MRSA), from the respiratory tract of people with CF who have persistent MRSA infections. Study participants will be randomly assigned to either the vancomycin for inhalation or placebo for inhalation. In addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Specimens of blood, sputum, and urine will be collected during the trial as well as pulmonary lung function testing.
>= 12 Years
>= 30 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.